Search Results for "arterial"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for arterial. Results 41 to 50 of 210 total matches.
Fenfluramine (Fintepla) for Dravet Syndrome
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
was
associated with an increased risk of pulmonary arterial
hypertension and cardiac valvulopathy.7 The labeling ...
The FDA has approved fenfluramine oral solution
(Fintepla – Zogenix) for treatment of seizures in
patients ≥2 years old with Dravet syndrome. It is the
third drug to be approved for this indication. Stiripentol
(Diacomit) and cannabidiol (Epidiolex), a purified
product derived from marijuana, were approved earlier.
Cilostazol for Intermittent Claudication
The Medical Letter on Drugs and Therapeutics • May 07, 1999 (Issue 1052)
Administration for treatment of intermittent claudication due to occlusive peripheral arterial disease ...
Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial disease.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
for rate control in patients with
coronary artery disease or systolic dysfunction. Verapamil
or diltiazem ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
Lepirudin for Heparin-Induced Thrombocytopenia
The Medical Letter on Drugs and Therapeutics • Sep 25, 1998 (Issue 1036)
, producing a
prothrombotic state. Untreated HIT can lead to venous and arterial thrombosis, pulmonary ...
Lepirudin (Refludan - Hoechst Marion Roussel), a direct inhibitor of thrombin, has been approved by the FDA for use as an anticoagulant in patients with heparin-induced thrombocytopenia and thromboembolic complications.
Durlaza - A 24-Hour Extended-Release Aspirin
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016 (Issue 1486)
with
diabetes and coronary artery disease (CAD) may have
high platelet turnover; a study in patients with CAD ...
The FDA has approved Durlaza (New Haven
Pharmaceuticals), a 24-hour extended-release (ER)
aspirin formulation available only by prescription, for
secondary prevention of myocardial infarction (MI)
and stroke.
Drugs for Intermittent Claudication
The Medical Letter on Drugs and Therapeutics • Feb 16, 2004 (Issue 1176)
symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic ...
Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608; RM Schainfeld, J Am Board Fam Pract 2001; 14:443).
A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021 (Issue 1640)
Dihydroergotamine is a
weaker arterial vasoconstrictor than ergotamine
and causes fewer serious adverse effects ...
The FDA has approved Trudhesa (Impel Neuropharma),
a new dihydroergotamine nasal spray
product, for acute treatment of migraine with or
without aura in adults. Another dihydroergotamine
nasal spray (Migranal, and generics) has been
available for many years for the same indication.
Fenoldopam--A New Drug for Parenteral Treatment of Severe Hypertension
The Medical Letter on Drugs and Therapeutics • May 22, 1998 (Issue 1027)
in spite of
the decrease in arterial pressure. In addition, fenoldopam has direct natriuretic and diuretic ...
Fenoldopam mesylte (Corlopam - Neurex), a peripheral dopamine-1 (DA1) agonist, has been approved by the FDA for parenteral use in lowering blood pressure. The manufacturer claims that, unlike other parenteral antihypertensive agents, fenoldopam not only lowers blood pressure but also maintains or improves renal function.
Dezocine
The Medical Letter on Drugs and Therapeutics • Oct 19, 1990 (Issue 829)
, pulmonary artery pressure, and
left ventricular stroke work, and some Medical Letter consultants believe ...
Dezocine (Dalgan - Astra), a new synthetic opioid agonist/antagonist structurally related to pentazocine (Talwin), was recently approved for parenteral use as an analgesic by the US Food and Drug Administration.
Laparoscopic Cholecystectomy
The Medical Letter on Drugs and Therapeutics • Dec 28, 1990 (Issue 834)
duct and artery are separated,
clipped, and divided. The gall bladder is dissected free ...
Unlike new drugs, new techniques for surgery do not need the approval of any government agency. Laparoscopic cholecystectomy, made possible by the development of miniaturized television cameras, is one such technique that has recently attracted widespread interest (LW Way, N Engl J Med, 323:1273, Nov 1, 1990; R Winslow, Wall St J, 216:1, Dec 10, 1990).